Annual Cost Of Goods Sold
$36.83 M
+$8.19 M+28.58%
December 1, 2024
Summary
- As of March 9, 2025, XERS annual cost of goods sold is $36.83 million, with the most recent change of +$8.19 million (+28.58%) on December 1, 2024.
- During the last 3 years, XERS annual cost of goods sold has risen by +$23.51 million (+176.56%).
- XERS annual cost of goods sold is now at all-time high.
Performance
XERS Cost Of Goods Sold Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cost Of Goods Sold
$9.48 M
-$4.12 M-30.27%
December 31, 2024
Summary
- As of March 9, 2025, XERS quarterly cost of goods sold is $9.48 million, with the most recent change of -$4.12 million (-30.27%) on December 31, 2024.
- Over the past year, XERS quarterly cost of goods sold has increased by +$1.69 million (+21.67%).
- XERS quarterly cost of goods sold is now -30.27% below its all-time high of $13.59 million, reached on September 30, 2024.
Performance
XERS Quarterly Cost Of Goods Sold Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM Cost Of Goods Sold
$36.83 M
+$1.91 M+5.46%
December 31, 2024
Summary
- As of March 9, 2025, XERS TTM cost of goods sold is $36.83 million, with the most recent change of +$1.91 million (+5.46%) on December 31, 2024.
- Over the past year, XERS TTM cost of goods sold has increased by +$7.30 million (+24.72%).
- XERS TTM cost of goods sold is now at all-time high.
Performance
XERS TTM Cost Of Goods Sold Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cost Of Goods Sold Formula
COGS = Beginning Inventory + Purchases − Ending Inventory
XERS Cost Of Goods Sold Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +28.6% | +21.7% | +24.7% |
| 3 y3 years | +176.6% | +15.6% | +34.6% |
| 5 y5 years | +2197.7% | +15.6% | +34.6% |
XERS Cost Of Goods Sold Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +176.6% | -30.3% | +97.0% | at high | +176.6% |
| 5 y | 5-year | at high | +2197.7% | -30.3% | +629.6% | at high | +2197.7% |
| alltime | all time | at high | >+9999.0% | -30.3% | >+9999.0% | at high | -100.0% |
Xeris Biopharma Holdings Cost Of Goods Sold History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | - | $9.48 M(-30.3%) | $36.83 M(+5.5%) |
| Dec 2024 | $36.83 M(+28.6%) | - | - |
| Sep 2024 | - | $13.59 M(+74.5%) | $34.92 M(+18.3%) |
| Jun 2024 | - | $7.79 M(+30.5%) | $29.53 M(+0.8%) |
| Mar 2024 | - | $5.97 M(-21.1%) | $29.30 M(+2.3%) |
| Dec 2023 | $28.64 M(+26.6%) | $7.57 M(-7.7%) | $28.64 M(+4.7%) |
| Sep 2023 | - | $8.20 M(+8.6%) | $27.37 M(+12.0%) |
| Jun 2023 | - | $7.55 M(+42.0%) | $24.43 M(+12.7%) |
| Mar 2023 | - | $5.32 M(-15.5%) | $21.68 M(-4.2%) |
| Dec 2022 | $22.63 M(+70.0%) | $6.29 M(+19.6%) | $22.63 M(+6.6%) |
| Sep 2022 | - | $5.26 M(+9.4%) | $21.23 M(+10.6%) |
| Jun 2022 | - | $4.81 M(-23.3%) | $19.19 M(+8.0%) |
| Mar 2022 | - | $6.27 M(+28.3%) | $17.77 M(+33.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | $13.32 M(+42.8%) | $4.89 M(+51.8%) | $13.32 M(+12.5%) |
| Sep 2021 | - | $3.22 M(-4.8%) | $11.84 M(+3.4%) |
| Jun 2021 | - | $3.38 M(+85.3%) | $11.45 M(+22.3%) |
| Mar 2021 | - | $1.83 M(-46.4%) | $9.36 M(+0.4%) |
| Dec 2020 | $9.33 M(+481.9%) | $3.41 M(+20.3%) | $9.33 M(+24.0%) |
| Sep 2020 | - | $2.83 M(+118.0%) | $7.52 M(+60.4%) |
| Jun 2020 | - | $1.30 M(-27.4%) | $4.69 M(+38.3%) |
| Mar 2020 | - | $1.79 M(+11.7%) | $3.39 M(+111.7%) |
| Dec 2019 | $1.60 M(>+9900.0%) | $1.60 M(-3916.7%) | $1.60 M(>+9900.0%) |
| Dec 2018 | - | -$42.00 K(-200.0%) | $0.00(-100.0%) |
| Mar 2018 | - | $42.00 K(+950.0%) | $46.00 K(+1050.0%) |
| Dec 2017 | $4000.00(-50.0%) | - | - |
| Jun 2017 | - | $4000.00 | $4000.00 |
| Dec 2016 | $8000.00 | - | - |
FAQ
- What is Xeris Biopharma Holdings annual cost of goods sold?
- What is the all time high annual cost of goods sold for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings annual cost of goods sold year-on-year change?
- What is Xeris Biopharma Holdings quarterly cost of goods sold?
- What is the all time high quarterly cost of goods sold for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings quarterly cost of goods sold year-on-year change?
- What is Xeris Biopharma Holdings TTM cost of goods sold?
- What is the all time high TTM cost of goods sold for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings TTM cost of goods sold year-on-year change?
What is Xeris Biopharma Holdings annual cost of goods sold?
The current annual cost of goods sold of XERS is $36.83 M
What is the all time high annual cost of goods sold for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high annual cost of goods sold is $36.83 M
What is Xeris Biopharma Holdings annual cost of goods sold year-on-year change?
Over the past year, XERS annual cost of goods sold has changed by +$8.19 M (+28.58%)
What is Xeris Biopharma Holdings quarterly cost of goods sold?
The current quarterly cost of goods sold of XERS is $9.48 M
What is the all time high quarterly cost of goods sold for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high quarterly cost of goods sold is $13.59 M
What is Xeris Biopharma Holdings quarterly cost of goods sold year-on-year change?
Over the past year, XERS quarterly cost of goods sold has changed by +$1.69 M (+21.67%)
What is Xeris Biopharma Holdings TTM cost of goods sold?
The current TTM cost of goods sold of XERS is $36.83 M
What is the all time high TTM cost of goods sold for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high TTM cost of goods sold is $36.83 M
What is Xeris Biopharma Holdings TTM cost of goods sold year-on-year change?
Over the past year, XERS TTM cost of goods sold has changed by +$7.30 M (+24.72%)